 Connection
David Fox to Fibrosis
This is a "connection" page, showing publications David Fox has written about Fibrosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.377 |
|
|
|
-
Muraoka S, Brodie WD, Mattichak MN, Gurrea-Rubio M, Ikari Y, Foster C, Amin MA, Khanna N, Amin H, Campbell PL, Vichaikul S, Model EN, Omara MM, Petrovski S, Kozicki K, Amarista C, Webber A, Ali M, Palisoc PJ, Hervoso J, Ruth JH, Tsoi LC, Varga J, Gudjonsson JE, Khanna D, Fox DA, Tsou PS. Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis. Arthritis Rheumatol. 2025 Jan; 77(1):80-91.
Score: 0.185
-
Tsou PS, Campbell P, Amin MA, Coit P, Miller S, Fox DA, Khanna D, Sawalha AH. Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. Proc Natl Acad Sci U S A. 2019 02 26; 116(9):3695-3702.
Score: 0.125
-
Vichaikul S, Gurrea-Rubio M, Amin MA, Campbell PL, Wu Q, Mattichak MN, Brodie WD, Palisoc PJ, Ali M, Muraoka S, Ruth JH, Model EN, Rohraff DM, Hervoso JL, Mao-Draayer Y, Fox DA, Khanna D, Sawalha AH, Tsou PS. Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight. 2022 05 09; 7(9).
Score: 0.039
-
Hutchings KM, Lisabeth EM, Rajeswaran W, Wilson MW, Sorenson RJ, Campbell PL, Ruth JH, Amin A, Tsou PS, Leipprandt JR, Olson SR, Wen B, Zhao T, Sun D, Khanna D, Fox DA, Neubig RR, Larsen SD. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 04 15; 27(8):1744-1749.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|